Doxorubicin is widely used as a chemotherapeutic agent against various human neoplasms, and it shows impressive anti-tumour activities. However, its use is restricted due to its cardiotoxic and undesirable side effects. In order to improve the pharmacodynamic properties of clinically-useful antitumour anthracyclines, new doxorubicin analogues that have lower toxicity but higher antitumour activity have been synthesised or isolated (Oki et al., 1975; Umezawa et al., 1979; Cassinelli et al., 1984; Weiss et al., 1987; Arcamone, 1987; Israel et al., 1987) . In Japan, the presently-used anthracycline derivatives are doxorubicin, epirubicin, pirarubicin, aclarubicin and daunorubicin. Recently, Tsuchiya et al. (1986 , 1988 reported ME2303 (Figure 1 ), a 2-fluoroglycoside of doxorubicin, which is more resistant to hydrolysis to aglycones and shows marked antitumour effects.
The liver is the primary site of metabolism of many drugs. The doxorubicin level in the liver is 100-fold higher than that in the plasma (Iguchi et al., 1985) . It would be interesting to know which anthracycline derivative is the most active against tumours in the liver. Moreover (Table IV) . The five-fraction regimen (every other day) caused toxic death. The nine-fraction dose regimen (days 7-15 daily) also showed toxicity, but the toxicity of this regimen was weaker than that of the fivefraction dose regimen (days 7, 9, 11, 13 and 15). The body weight of the mice recovered after more than 2 weeks after stopping the treatment, but the hepatic neoplastic nodules regrew. Moreover, when compared with three-and fivefraction dose regimens in normal CDF, mice treated with same total doses of ME2303, the body weight with the five-fraction regimen was markedly decreased compared with the three-fraction regimen (Figure 3 ), like in tumour-bearing mice. This result means that the three-fraction dose regimen is lower in toxicity than the five-fraction regimen.
Discussion
In this study, we investigated the antitumour effect of five anthracycline derivatives (doxorubicin, epirubicin, pirarubicin, aclarubicin and ME2303) against hepatic nodules of Lewis lung carcinoma and colon adenocarcinoma'26. The hepatic nodules of Lewis lung carcinoma were well inhibited by pirarubicin and ME2303. These drugs produced many 'cured' mice when the drugs were injected on day 4 or on days 4, 8 and 12, while there were only a few cured mice in the group treated with doxorubicin using the same schedule. Colon adenocarcinoma 26 cells were inoculated into the liver by intrasplenic inoculation, and drugs were administered i.v. on days 7, 11 and 15. aMST, mean survival time of deceased mice; bNumber of cured mice per treated mice, on day 80; cMean + s.e.; dp <0.05 compared to Control; eP< 0.01; fp < 0.0i. On the other hand, no mice were cured by treatment with epirubicin or aclarubicin. Moreover, delayed treatment with doxorubicin, pirarubicin and ME2303, on days 7, 11, and 15, showed much more different effect on survival of the tumourbearing mice. Many mice were cured by the optimal dose of ME2303, but none were cured by any dose of doxorubicin or pirarubicin.
Thus, ME2303 resulted in many cured mice even in the advanced stage of hepatic neoplastic nodules, while in the treatment of doxorubicin and pirarubicin cured mice were observed at high frequency only in the early stage of tumour growth in the liver.
When the therapeutic ratio (the dose showing maximum ILS/the dose showing 30% ILS) (Hoshi et al., 1976) was calculated from Table II , those of doxorubicin, pirarubicin and ME2303 were about 1.2, 2.3 and 6.0, respectively. Thus, the therapeutic ratio of ME2303 was 5-fold greater than that of doxorubicin. Moreover, using the hepatic nodule model of colon adenocarcinoma 26, we found that ME2303 also shows a superior antitumour effect compared with doxorubicin and pirarubicin. Namely, the ILS with ME2303 was greater than that with doxorubicin at optimal doses by i.v. administration, although there were few mice cured by the treatment with these anthracycline derivatives. Thus, ME2303 was the most active agent in mice with hepatic nodules of both Lewis lung carcinoma and colon adenocarcinoma 26, while doxorubicin was not very effective. As the optimal treatment regimen, three injections, every 4th day, may be considered in the chemotherapy of liver tumours. Greater fractionation of the dosage regimen and a shorter interval between doses were observed to cause lethal toxicity in many mice.
In an in vitro experiment (Tsuruo et al., 1989) , ME2303 had a cytotoxic effect similar to that of doxorubicin against P388 leukemia, and ME2303 showed a marked antitumour effect against i.p.-inoculated tumour cells compared to doxorubicin. Although in vitro experiments on ME2303 have not been performed against the Lewis lung carcinoma and colon adenocarcinoma 26 cell lines, ME2303's antimetastatic effect may be due to better delivery of the drug to the tumour in the liver.
